{"id":15417,"date":"2019-10-03T18:21:19","date_gmt":"2019-10-03T16:21:19","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=15417"},"modified":"2019-10-08T18:33:50","modified_gmt":"2019-10-08T16:33:50","slug":"curie-capital-invests-in-allero-therapeutics","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/","title":{"rendered":"Curie Capital invests in Allero Therapeutics"},"content":{"rendered":"\n

Life sciences seed capital fund Curie Capital today announced<\/g> the closing of a seed investment in Allero<\/g> Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform technology, called Specific Oromucosal Immunotherapy (SOMIT), which enables targeted delivery of antigen-specific immunotherapies to the oromucosa<\/g> (a specialized compartment of the immune system that lines the inside of the mouth). Allero<\/g> Therapeutics aims to restore immune tolerance for specific target molecules in patients suffering from allergic and autoimmune diseases.<\/p>\n\n\n\n

Combined with the recent funding from Swanbridge Capital, Curie Capital\u2019s seed investment will enable Allero<\/g> Therapeutics to prepare its lead product for clinical development including the manufacturing process for clinical-grade products. \u201cWe are excited to have another life sciences fund on board.<\/g>\u201d said Emil Pot, Allero<\/g> Therapeutics\u2019 CEO. He added: \u201cThis allows us to speed up key development milestones, which will pave the way for further accelerated (clinical) development of SOMIT products\u201d.<\/p>\n\n\n\n

Mari\u00ebtte van der Velden, Managing<\/g> Partner of Curie Capital, said: \u201cWe are very excited to support Allero<\/g> Therapeutics to develop SOMIT. The platform technology is based on a smart combination of product components known to be safe in humans. If the clinical trial of SOMIT in a first indication shows proof of tolerance induction, it would mean that the growing number of allergic patients can finally look forward to an easy to administer short-course treatment. In addition, it would provide a strong indication that a curative solution for specific autoimmune diseases can be developed\u201c.<\/p>\n\n\n\n

Professor Lars K. Poulsen, a leading clinical researcher and Key Opinion Leader in the area of Allergen Immunotherapy (AIT) of the Copenhagen University Hospital said: \u201cThere are still neither preventive nor curative treatments available for food allergies and autoimmune diseases, and the prospect of targeting the disease with SOMIT with its combination of specific antigens and modulation of the immune system is very promising and novel.\u201d<\/p>\n\n\n\n

Source: Allero Therapeutics<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform technology, called Specific Oromucosal Immunotherapy (SOMIT), which enables targeted delivery of antigen-specific immunotherapies to the oromucosa (a specialized compartment of […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-15417","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"\nCurie Capital invests in Allero Therapeutics - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curie Capital invests in Allero Therapeutics - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform technology, called Specific Oromucosal Immunotherapy (SOMIT), which enables targeted delivery of antigen-specific immunotherapies to the oromucosa (a specialized compartment of […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-03T16:21:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-10-08T16:33:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Curie Capital invests in Allero Therapeutics\",\"datePublished\":\"2019-10-03T16:21:19+00:00\",\"dateModified\":\"2019-10-08T16:33:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/\"},\"wordCount\":327,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/\",\"name\":\"Curie Capital invests in Allero Therapeutics - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-10-03T16:21:19+00:00\",\"dateModified\":\"2019-10-08T16:33:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/curie-capital-invests-in-allero-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curie Capital invests in Allero Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curie Capital invests in Allero Therapeutics - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Curie Capital invests in Allero Therapeutics - hollandbio","og_description":"Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform technology, called Specific Oromucosal Immunotherapy (SOMIT), which enables targeted delivery of antigen-specific immunotherapies to the oromucosa (a specialized compartment of […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/","og_site_name":"hollandbio","article_published_time":"2019-10-03T16:21:19+00:00","article_modified_time":"2019-10-08T16:33:50+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Curie Capital invests in Allero Therapeutics","datePublished":"2019-10-03T16:21:19+00:00","dateModified":"2019-10-08T16:33:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/"},"wordCount":327,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/","name":"Curie Capital invests in Allero Therapeutics - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-10-03T16:21:19+00:00","dateModified":"2019-10-08T16:33:50+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/curie-capital-invests-in-allero-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Curie Capital invests in Allero Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=15417"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15417\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=15417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=15417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=15417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}